Page last updated: 2024-10-19

niacinamide and Exanthem

niacinamide has been researched along with Exanthem in 14 studies

nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.

Research Excerpts

ExcerptRelevanceReference
" However, there is lack of data in sorafenib-treated patients with advanced hepatocellular carcinoma (HCC)."9.20Liver function assessment according to the Albumin-Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma. ( Chiba, T; Kanai, F; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Saito, T; Suzuki, E; Tawada, A; Yokosuka, O, 2015)
"We report a 63-year-old Caucasian male who developed multiple cutaneous eruptive keratoacanthomas after starting sorafenib 400 mg twice daily."8.02Sorafenib-related generalized eruptive keratoacanthomas (Grzybowski syndrome): a case report. ( Abbas, MN; Kichenadasse, G; Tan, WS, 2021)
" Sorafenib concentrations were significantly greater in patients with grade ≥2 HFSR and hypertension than in those not experiencing the adverse events (p = 0."7.80Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma. ( Chiba, T; Fukudo, M; Hatano, E; Ito, T; Kamba, T; Matsubara, K; Mizuno, T; Ogawa, O; Seno, H; Shinsako, K; Uemoto, S; Yamasaki, T, 2014)
"Sorafenib is an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases and has led to a longer median overall survival (OS) time and time to progression (TTP) in patients with advanced hepatocellular carcinoma (HCC)."7.76Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. ( Addeo, R; Caraglia, M; Colucci, G; Del Prete, S; Frezza, AM; Giuliani, F; Montella, L; Rizzo, S; Russo, A; Santini, D; Tonini, G; Venditti, O; Vincenzi, B, 2010)
" The primary endpoint was disease control rate (DCR) at week 12, and the secondary endpoints included time to progression (TTP), progression-free survival (PFS), overall survival (OS), duration of therapy (DOT), and adverse events (AEs)."6.84Effectiveness and safety of sorafenib in the treatment of unresectable and advanced intrahepatic cholangiocarcinoma: a pilot study. ( Gao, C; Huang, Z; Jia, W; Jiang, X; Lau, WY; Li, J; Li, X; Luo, X; Shen, F; Si, A; Xing, B; Yang, T, 2017)
" However, there is lack of data in sorafenib-treated patients with advanced hepatocellular carcinoma (HCC)."5.20Liver function assessment according to the Albumin-Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma. ( Chiba, T; Kanai, F; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Saito, T; Suzuki, E; Tawada, A; Yokosuka, O, 2015)
" Sorafenib and sunitinib are two of these novel agents, acting on tumour angiogenesis as well as on other key proliferative pathways; recently approved for the treatment of advanced kidney cancer, they may cause peculiar cutaneous, vascular and mucosal toxicities, including hand-foot skin reaction, skin rash, hypertension and GERD-like oesophagitis/gastritis."4.84Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. ( Bonomi, L; Imarisio, I; Paglino, C; Porta, C, 2007)
"We report a 63-year-old Caucasian male who developed multiple cutaneous eruptive keratoacanthomas after starting sorafenib 400 mg twice daily."4.02Sorafenib-related generalized eruptive keratoacanthomas (Grzybowski syndrome): a case report. ( Abbas, MN; Kichenadasse, G; Tan, WS, 2021)
" Sorafenib concentrations were significantly greater in patients with grade ≥2 HFSR and hypertension than in those not experiencing the adverse events (p = 0."3.80Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma. ( Chiba, T; Fukudo, M; Hatano, E; Ito, T; Kamba, T; Matsubara, K; Mizuno, T; Ogawa, O; Seno, H; Shinsako, K; Uemoto, S; Yamasaki, T, 2014)
"Sorafenib is an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases and has led to a longer median overall survival (OS) time and time to progression (TTP) in patients with advanced hepatocellular carcinoma (HCC)."3.76Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. ( Addeo, R; Caraglia, M; Colucci, G; Del Prete, S; Frezza, AM; Giuliani, F; Montella, L; Rizzo, S; Russo, A; Santini, D; Tonini, G; Venditti, O; Vincenzi, B, 2010)
" The primary endpoint was disease control rate (DCR) at week 12, and the secondary endpoints included time to progression (TTP), progression-free survival (PFS), overall survival (OS), duration of therapy (DOT), and adverse events (AEs)."2.84Effectiveness and safety of sorafenib in the treatment of unresectable and advanced intrahepatic cholangiocarcinoma: a pilot study. ( Gao, C; Huang, Z; Jia, W; Jiang, X; Lau, WY; Li, J; Li, X; Luo, X; Shen, F; Si, A; Xing, B; Yang, T, 2017)
" In order to assess the safety of sorafenib in PAH, patients with advanced but stable disease on parenteral prostanoids (with or without oral sildenafil) were initiated on treatment at the lowest active dosage administered to cancer patients: 200 mg daily."2.75A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension. ( Archer, SL; Barst, RJ; Bond, L; Coslet, S; Gomberg-Maitland, M; Lacouture, ME; Maitland, ML; Perrino, TJ; Ratain, MJ; Sugeng, L, 2010)
"Cutaneous adverse events commonly reported with tyrosine kinase inhibitors (TKIs) in the treatment of malignancies, represent an important clinical concern since they can limit the optimal use of these novel drugs."2.48Early detection, prevention and management of cutaneous adverse events due to sorafenib: recommendations from the Sorafenib Working Group. ( Bracarda, S; Cortesi, E; D'Angelo, A; Ferraù, F; Merlano, M; Monti, M; Ruggeri, EM; Santoro, A, 2012)
"Sorafenib is a novel oral bis-aryl urea compound originally developed as an inhibitor of RAF kinase for its anti-proliferative property."2.46Toxicity of sorafenib: clinical and molecular aspects. ( Barete, S; Billemont, B; Blanchet, B; Cabanes, L; Coriat, R; Francès, C; Garrigue, H; Goldwasser, F; Knebelmann, B, 2010)
"Sorafenib was well tolerated at the RDP, and induced sustained disease stabilization, particularly in patients with skin toxicity/diarrhoea."2.43Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome? ( Awada, A; Brueckner, A; Christensen, O; Clark, JW; Hirte, H; Hofstra, E; Piccart, P; Schwartz, B; Seeber, S; Strumberg, D; Voliotis, D, 2006)
" The dosage was temporarily reduced in only two patients, and oral steroids were added in four."1.43Widespread morbilliform rash due to sorafenib or vemurafenib treatment for advanced cancer; experience of a tertiary dermato-oncology clinic. ( Amitay-Laish, I; Didkovsky, E; Hendler, D; Hodak, E; Lotem, M; Merims, S; Ollech, A; Popovtzer, A; Stemmer, SM, 2016)
"A retrospective, registry-based analysis to assess the outcomes of metastatic renal cell cancer (mRCC) patients treated with sunitinib and sorafenib who developed dermatologic adverse events was performed."1.38Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study. ( Abrahamova, J; Bortlicek, Z; Buchler, T; Dusek, L; Melichar, B; Pavlik, T; Poprach, A; Puzanov, I; Vyzula, R, 2012)

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (21.43)29.6817
2010's10 (71.43)24.3611
2020's1 (7.14)2.80

Authors

AuthorsStudies
Abbas, MN1
Tan, WS1
Kichenadasse, G1
Fukudo, M1
Ito, T1
Mizuno, T1
Shinsako, K1
Hatano, E1
Uemoto, S1
Kamba, T1
Yamasaki, T1
Ogawa, O1
Seno, H1
Chiba, T2
Matsubara, K1
Ogasawara, S1
Ooka, Y1
Suzuki, E1
Kanogawa, N1
Saito, T1
Motoyama, T1
Tawada, A1
Kanai, F1
Yokosuka, O1
Ollech, A1
Stemmer, SM1
Merims, S1
Lotem, M1
Popovtzer, A1
Hendler, D1
Hodak, E1
Didkovsky, E1
Amitay-Laish, I1
Luo, X1
Jia, W1
Huang, Z1
Li, X1
Xing, B1
Jiang, X1
Li, J1
Si, A1
Yang, T1
Gao, C1
Lau, WY1
Shen, F1
Gomberg-Maitland, M1
Maitland, ML1
Barst, RJ1
Sugeng, L1
Coslet, S1
Perrino, TJ1
Bond, L1
Lacouture, ME1
Archer, SL1
Ratain, MJ1
Vincenzi, B1
Santini, D1
Russo, A1
Addeo, R1
Giuliani, F1
Montella, L1
Rizzo, S1
Venditti, O1
Frezza, AM1
Caraglia, M1
Colucci, G1
Del Prete, S1
Tonini, G1
Blanchet, B1
Billemont, B1
Barete, S1
Garrigue, H1
Cabanes, L1
Coriat, R1
Francès, C1
Knebelmann, B1
Goldwasser, F1
Bracarda, S1
Ruggeri, EM1
Monti, M1
Merlano, M1
D'Angelo, A1
Ferraù, F1
Cortesi, E1
Santoro, A1
Poprach, A1
Pavlik, T1
Melichar, B1
Puzanov, I1
Dusek, L1
Bortlicek, Z1
Vyzula, R1
Abrahamova, J1
Buchler, T1
Tsuchiya, N1
Narita, S1
Inoue, T1
Hasunuma, N1
Numakura, K1
Horikawa, Y1
Satoh, S1
Notoya, T1
Fujishima, N1
Hatakeyama, S1
Ohyama, C1
Habuchi, T1
Hilger, RA1
Kredtke, S1
Scheulen, ME1
Seeber, S2
Strumberg, D2
Awada, A1
Hirte, H1
Clark, JW1
Piccart, P1
Hofstra, E1
Voliotis, D1
Christensen, O1
Brueckner, A1
Schwartz, B1
Porta, C1
Paglino, C1
Imarisio, I1
Bonomi, L1

Reviews

4 reviews available for niacinamide and Exanthem

ArticleYear
Toxicity of sorafenib: clinical and molecular aspects.
    Expert opinion on drug safety, 2010, Volume: 9, Issue:2

    Topics: Animals; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Exanthema; Humans; Kidn

2010
Early detection, prevention and management of cutaneous adverse events due to sorafenib: recommendations from the Sorafenib Working Group.
    Critical reviews in oncology/hematology, 2012, Volume: 82, Issue:3

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Disease M

2012
Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?
    European journal of cancer (Oxford, England : 1990), 2006, Volume: 42, Issue:4

    Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Clinical Tr

2006
Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib.
    Clinical and experimental medicine, 2007, Volume: 7, Issue:4

    Topics: Acneiform Eruptions; Antineoplastic Agents; Benzenesulfonates; Erythema; Esophagitis; Exanthema; Hum

2007

Trials

5 trials available for niacinamide and Exanthem

ArticleYear
Liver function assessment according to the Albumin-Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma.
    Investigational new drugs, 2015, Volume: 33, Issue:6

    Topics: Antineoplastic Agents; Bilirubin; Carcinoma, Hepatocellular; Disease Progression; Exanthema; Fatigue

2015
Effectiveness and safety of sorafenib in the treatment of unresectable and advanced intrahepatic cholangiocarcinoma: a pilot study.
    Oncotarget, 2017, Mar-07, Volume: 8, Issue:10

    Topics: Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Diarrhea; Drug Administrati

2017
A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension.
    Clinical pharmacology and therapeutics, 2010, Volume: 87, Issue:3

    Topics: Adult; Aged; Benzenesulfonates; Diarrhea; Drug Discovery; Drug Dosage Calculations; Exanthema; Femal

2010
Risk factors for sorafenib-induced high-grade skin rash in Japanese patients with advanced renal cell carcinoma.
    Anti-cancer drugs, 2013, Volume: 24, Issue:3

    Topics: Aged; Antineoplastic Agents; Asian People; ATP Binding Cassette Transporter, Subfamily B; ATP Bindin

2013
Correlation of ERK-phosphorylation and toxicities in patients treated with the Raf kinase inhibitor BAY 43-9006.
    International journal of clinical pharmacology and therapeutics, 2004, Volume: 42, Issue:11

    Topics: Adult; Area Under Curve; Benzenesulfonates; Diarrhea; Drug Administration Schedule; Exanthema; Human

2004

Other Studies

5 other studies available for niacinamide and Exanthem

ArticleYear
Sorafenib-related generalized eruptive keratoacanthomas (Grzybowski syndrome): a case report.
    Journal of medical case reports, 2021, Sep-21, Volume: 15, Issue:1

    Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Exanthema; Humans; Keratoacanthoma; Male; Middle Ag

2021
Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma.
    Clinical pharmacokinetics, 2014, Volume: 53, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Hepatocellular; Carc

2014
Widespread morbilliform rash due to sorafenib or vemurafenib treatment for advanced cancer; experience of a tertiary dermato-oncology clinic.
    International journal of dermatology, 2016, Volume: 55, Issue:4

    Topics: Aged; Antineoplastic Agents; Drug Eruptions; Exanthema; Female; Humans; Indoles; Male; Middle Aged;

2016
Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib.
    The oncologist, 2010, Volume: 15, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular;

2010
Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:12

    Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival;

2012